InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.058 0.055 (1,833.33%)+
Announcement
Release
2 Oct 2025 9:42AM
Price at Release
$0.003
Full Release
download
Summary
Chimeric Therapeutics Limited announced the achievement of additional complete responses in its CORE-NK Phase 1b clinical trial for acute myeloid leukemia (AML), conducted as part of the ADVENT-AML trial. The trial evaluated the safety and efficacy of CORE-NK cells in combination with standard AML treatments, demonstrating positive clinical responses in 57% of high-risk frontline subjects. This includes two new complete responses, adding to the previously reported results. The trial is currently enrolling patients at MD Anderson Cancer Center and Case Western Reserve University, focusing on high-risk patients with newly diagnosed AML. The CORE-NK therapy has continued to show a favorable safety profile, and no unexpected adverse safety findings have been reported. Chimeric Therapeutics is optimistic about the potential of this therapy to significantly impact current clinical practices for AML treatment.
Key Points
  • Chimeric Therapeutics achieves additional complete responses in CORE-NK Phase 1b trial for AML.
  • 57% of high-risk frontline subjects showed clinical responses.
  • Two new complete responses were reported, supplementing previous findings.
  • The ongoing trial is enrolling patients at MD Anderson Cancer Center and Case Western Reserve University.
  • Combination treatment includes CORE-NK cells with azacitidine and venetoclax.
  • The trial continues to show favorable safety with no unexpected adverse findings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.